Next-Generation CAR T-Cell Therapy for GBM
| Property | Information |
|---|---|
| Drug Name | Next-Generation CAR T-Cell Therapy for GBM |
| FDA Approval | In trial phase for GBM; FDA-approved for other cancers |
| Used for | Recurrent Glioblastoma Multiforme (GBM) |
| Clinical Trial Phase | Phase 1 (INCIPIENT trial among others) |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Fevers, altered mental status shortly after infusion, significant but manageable neurotoxicity |
| OS without | Median survival for recurrent GBM typically less than one year |
| OS with | Not fully established; dramatic and rapid tumor regression observed in initial patients |
| PFS without | Not specified |
| PFS with | Significant reduction in tumor size noted, durability of response under investigation |
| Usefulness Rating | 4 |
| Usefulness Explanation | Introduces a novel, highly personalized approach targeting mixed cell populations within GBM tumors. Early results demonstrate potential for substantial impact on tumor reduction and patient outcomes, indicating a promising direction for future GBM treatment strategies.Property "Has Usefulness Explanation" (as page type) with input value "Introduces a novel, highly personalized approach targeting mixed cell populations within GBM tumors. Early results demonstrate potential for substantial impact on tumor reduction and patient outcomes, indicating a promising direction for future GBM treatment strategies." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process. |
| Toxicity Level | 3 |
| Toxicity Explanation | Includes expected side effects such as fevers and altered mental status post-infusion, with significant neurotoxicity that has been manageable in initial patients. |
From Ben Williams Book: Recent advancements in CAR T-cell therapy, particularly the innovative approach taken in the INCIPIENT trial, have shown promising early results for treating GBM. By targeting mixed cell populations within tumors and observing dramatic reductions in tumor size, this therapy represents a potential breakthrough in GBM treatment. While further research is needed to understand long-term effectiveness and manage side effects, these early findings provide hope for more effective GBM therapies. Ben Williams book: Chimeric antigen receptor (CAR) T-cells are T-cells that have been genetically engineered, commonly by the use of a retroviral vector, to express artificial receptors specifically targeted to a chosen tumor-associated or tumor-specific antigen. CAR T-cells directed to CD19 have been used with impressive success for B-cell acute lymphoblastic leukemia (ALL), and tisagenlecleucel, an anti-CD19 CAR T-cell therapy was approved for this indication on August 30, 2017. For glioblastoma, phase 1 CAR T-cell trials are currently active, with preliminary outcomes now published for two of these trials, as discussed below.Property "Has original text" (as page type) with input value "Recent advancements in CAR T-cell therapy, particularly the innovative approach taken in the INCIPIENT trial, have shown promising early results for treating GBM. By targeting mixed cell populations within tumors and observing dramatic reductions in tumor size, this therapy represents a potential breakthrough in GBM treatment. While further research is needed to understand long-term effectiveness and manage side effects, these early findings provide hope for more effective GBM therapies.</br>Ben Williams book: Chimeric antigen receptor (CAR) T-cells are T-cells that have been genetically engineered,</br>commonly by the use of a retroviral vector, to express artificial receptors specifically</br>targeted to a chosen tumor-associated or tumor-specific antigen. CAR T-cells directed to</br>CD19 have been used with impressive success for B-cell acute lymphoblastic leukemia</br>(ALL), and tisagenlecleucel, an anti-CD19 CAR T-cell therapy was approved for this</br>indication on August 30, 2017. For glioblastoma, phase 1 CAR T-cell trials are currently</br>active, with preliminary outcomes now published for two of these trials, as discussed</br>below." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.
